Physician profile
John A Pasquini
NPI 1740288059
$32,302.13
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $6,342 · 2021: $6,577 · 2022: $6,915 · 2023: $868.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $701 · Food and Beverage: $167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $700.50 |
| Food and Beverage | $167.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30,963.40 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $295.01 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $237.99 | 2019-2023 | |
| Edwards Lifesciences Corporation | $142.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $124.15 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $112.15 | 2019 | |
| Sanofi-Aventis U.S. LLC | $108.26 | 2019 | |
| Akcea Therapeutics, INC. | $103.12 | 2019 | |
| Boston Scientific Corporation | $94.96 | 2019-2021 | |
| Ekos Corporation | $92.23 | 2019 | |
| Heartflow, INC. | $15.64 | 2023 | Ffrct |
| Abbott Laboratories | $12.38 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Pasquini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.